The medical technology company, Tecan, said on Tuesday that its sales grew by 42 per cent last year to SFr273 million ($166 million).
Sales were particularly strong in the fourth quarter and rose by 48 per cent.
The company said it expected continued growth in 2001 because of strong demand from the pharmaceutical and biotechnology industries in the United States and Europe.
Last week, Tecan announced an increased focus on proteomics, the study of how information contained in genes is translated into proteins and how they interact to foster health or trigger disease.
It announced the launch of a proteomics division and the purchase of a specialist company in Germany.
swissinfo with agencies